Can Thailand's Third-Generation IVF Screen for Genetic Diseases? Analysis of PGT Technology Principles and Applicable Populations
Opening: Physician's Clinical Decision-Making Logic
In the outpatient clinic, a couple presented: the wife was 34 years old, the husband 37, and both were carriers of α-thalassemia (--SEA/αα). They had two natural pregnancies, both terminated in the second trimester due to fetal hydrops syndrome. The couple, holding a thick stack of test reports, asked: "Doctor, if we go to Thailand for third-generation IVF, can we completely solve the genetic disease problem and guarantee a healthy child?" Behind this question lies a common misunderstanding of the boundaries of Preimplantation Genetic Testing (PGT) technology. As a reproductive physician, it is necessary to deconstruct what PGT can and cannot do from the fundamental principles of genetics, as well as the key points often overlooked during overseas medical treatment.
Can Thailand's Third-Generation IVF Screen for Genetic Diseases: Technical Boundaries and Detection Scope
Thailand's third-generation IVF technology, known as Preimplantation Genetic Testing (PGT), can screen for specific types of genetic diseases, but it cannot detect "all genetic diseases." PGT is divided into three subtypes based on the purpose of testing:
- PGT-A (Aneuploidy Screening): Detects whether embryos have chromosomal number abnormalities, such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sex chromosome number abnormalities. Suitable for women of advanced maternal age, those with recurrent miscarriage, and those with repeated implantation failure.
- PGT-M (Monogenic Disease Screening): Targets monogenic disorders with a clearly identified causative gene, such as thalassemia, spinal muscular atrophy (SMA), Huntington's disease, Marfan syndrome, and hemophilia. It requires prior confirmation of the pathogenic gene mutation site within the family to design personalized testing probes.
- PGT-SR (Structural Rearrangement Screening): Detects structural abnormalities like balanced translocations, Robertsonian translocations, and inversions. Suitable for carriers with abnormal karyotype analysis.
Some reproductive centers in Thailand offer combined PGT-A + PGT-M testing, or additionally include mitochondrial DNA testing (for mitochondrial disease screening). However, the latter is still within the realm of clinical research and is offered by a limited number of centers.
Core Conclusion: Thailand's third-generation IVF can screen for chromosomal number abnormalities, monogenic diseases with clearly identified causative genes, and chromosomal structural rearrangements. However, polygenic disorders (such as diabetes, hypertension, schizophrenia, autism spectrum disorder) and diseases caused by environmental factors are not within the scope of PGT testing.
Sources of Cognitive Bias: The Gap Between Market Promotion and Medical Reality
The statement "third-generation IVF can screen for genetic diseases" is not incorrect in itself, but it has been simplified and exaggerated during dissemination. Some market institutions package PGT as a "universal embryo filter," implying it can "eliminate all unhealthy embryos" and "guarantee an absolutely healthy child." Such promotion ignores several key facts:
- Detection Accuracy Limitations: Embryo biopsy only obtains 5-10 trophectoderm cells. During DNA amplification, allele drop-out (ADO) or amplification failure can occur, leading to misdiagnosis or inconclusive results. The overall misdiagnosis rate for PGT is approximately 1%–2%. Accurate assessment of mosaic embryos (coexistence of normal and abnormal cells) remains a technical challenge.
- Vast Number of Genetic Diseases: There are over 8,000 known monogenic disorders, but only about 5,000 have clinically available detection methods, which require family verification. For rare mutations, probes may not be designable.
- Unpredictability of Polygenic Diseases: Most common chronic diseases and neurodevelopmental disorders result from the interaction of multiple genes and environmental factors. PGT cannot assess such risks.
- Irreplaceability of Prenatal Diagnosis: PGT results are not a final diagnosis. All pregnancies following PGT still require confirmation through amniocentesis or chorionic villus sampling for prenatal karyotyping.
When patients come to the clinic with the expectation of "eradicating genetic diseases," the physician's role is to clearly explain the technical boundaries, rather than reinforcing unrealistic expectations.
Clinical Decision-Making Logic: When Do Physicians Recommend PGT?
From a reproductive medicine perspective, the clinical application of PGT requires strict adherence to indications. The clinical guidelines for PGT in Thailand and China are generally consistent, but regulatory and ethical review processes differ. When recommending PGT, physicians comprehensively evaluate the following dimensions:
| Evaluation Dimension | Specific Content | Clinical Significance |
|---|---|---|
| Female Age | ≥38 years | Significantly increased rate of oocyte chromosomal aneuploidy; PGT-A can select euploid embryos, reducing miscarriage rate. |
| Genetic Disease Carrier Status | One or both partners are carriers of a monogenic disorder | Family genetic testing must be completed first to confirm the pathogenic mutation before PGT-M can be performed. |
| Chromosomal Karyotype Abnormality | Balanced translocation, Robertsonian translocation, inversion, etc. | PGT-SR can select embryos with normal chromosomal structure, improving implantation success rate. |
| Previous Pregnancy History | ≥2 early miscarriages, history of fetal malformation, history of giving birth to a child with genetic disease | PGT can reduce the risk of recurrence of similar adverse pregnancy outcomes. |
| Ovarian Reserve Function | AMH, basal FSH, antral follicle count | The number of retrieved oocytes directly affects the number of embryos available for testing. When AMH < 1.0 ng/mL, the cost-effectiveness of PGT needs assessment. |
In Thailand, some reproductive centers also offer PGT for "social indications" (such as sex selection, HLA matching), but this is ethically controversial and not recognized by all countries. From a purely medical perspective, the priority candidates for PGT are patients with a clear genetic risk.
Easily Overlooked Technical Details: Detection Accuracy and Inherent Limitations
In clinical consultations, the following details are often overlooked by patients and even some practitioners, yet they directly impact the interpretation of test results and embryo transfer decisions:
- The Dilemma of Assessing Mosaic Embryos: Early in development, embryos may exhibit a coexistence of normal and abnormal cells. The 5-10 cells biopsied for PGT may not represent the true karyotype of the entire embryo. Currently, for low-level mosaicism with a mosaic ratio < 20%, some centers consider transfer feasible, but close prenatal follow-up is required; embryos with a mosaic ratio > 50% are generally not recommended for transfer. Strategies for handling mosaicism vary significantly between centers.
- Barriers to Detecting Mitochondrial Genetic Diseases: Mitochondrial diseases are caused by mtDNA mutations and follow maternal inheritance. Conventional PGT cannot detect mitochondrial mutations; specialized techniques like mitochondrial replacement or polar body biopsy are required, which are currently only performed in a few laboratories.
- Design Cycle for Genetic Testing Probes: PGT-M requires designing personalized probes based on the couple's pathogenic genes, typically taking 4-8 weeks. If key family members (e.g., affected relatives who have passed away) are unavailable, the linkage between the pathogenic gene and haplotype may not be confirmed, leading to probe design failure.
- Potential Impact of Embryo Biopsy on Developmental Potential: Although blastocyst-stage biopsy (taking trophectoderm cells) is considered to have minimal impact on the inner cell mass, some studies suggest that biopsy may reduce the implantation and live birth rate by approximately 5%–10%. This factor needs to be weighed in clinical decision-making.
Common Cognitive Misconceptions and Risk Points in Overseas Medical Treatment
Based on follow-ups with hundreds of overseas medical patients, the following six misconceptions are most frequent and can directly lead to treatment failure or unnecessary expenses:
- Believing PGT can screen for "all" genetic diseases. Fact: Polygenic disorders, de novo mutations, and rare mutations may not be detectable or validated.
- Ignoring the importance of domestic genetic counseling and family verification. Some patients go directly to Thailand for PGT, only to find that the Thai side cannot complete the family study, requiring them to return to China to do it, wasting time and cycles.
- Equating PGT with "100% healthy baby." PGT cannot rule out congenital anomalies caused by non-genetic factors such as intrauterine infections, drug teratogenicity, or birth injuries.
- Underestimating the interference of chromosomal mosaicism in transfer decisions. After receiving a "mosaic embryo" report, patients are unsure how to proceed. Some centers recommend transfer but provide inadequate risk disclosure, leading to later anxiety.
- Neglecting document and cycle preparation for overseas medical treatment. Thailand's third-generation IVF requires a medical visa (typically a 30-day stay), a passport valid for >6 months, and advance preparation of marriage certificate, passport translation, and notarized documents. Incomplete documentation can delay cycle initiation.
- Thinking "low AMH means you can't do overseas IVF." Low AMH only indicates reduced ovarian reserve, not an absolute contraindication for PGT. Patients over 38 with AMH < 0.8 ng/mL can still undergo egg retrieval, though the number of embryos available for testing may be limited. Expectation management is crucial during consultation.
Complete Process and Timeline for Thailand's Third-Generation IVF PGT
The following process uses a single cycle of PGT-A/PGT-M as an example. Actual arrangements may vary slightly depending on the center and individual circumstances:
| Stage | Specific Steps | Time Required | Notes |
|---|---|---|---|
| Preparation Period | Genetic counseling, family genetic testing, karyotype analysis, AMH+FSH+LH+antral follicle count, semen analysis, infectious disease screening, uterine cavity examination (if indicated), passport validity check, marriage certificate notarization and translation, file creation | 4–8 weeks | Some test results are valid for 6–12 months (e.g., infectious disease screening, karyotype), so timing with the cycle is necessary. |
| Ovarian Stimulation | Start stimulation on day 2–3 of menstruation, monitor follicle development regularly, adjust medication dosage | 10–14 days | Thailand's hot climate requires attention to heat prevention and food hygiene to avoid infections affecting oocyte quality. |
| Egg Retrieval and Fertilization | Transvaginal ultrasound-guided oocyte retrieval, same-day sperm collection, ICSI fertilization | 1 day | Rest for 2–4 hours after retrieval; avoid strenuous activity. |
| Embryo Culture and Biopsy | Culture embryos to blastocyst stage (day 5–6), trophectoderm cell biopsy, vitrification | 5–6 days | Biopsy requires laser assistance and demands high laboratory equipment and personnel skills. |
| Genetic Testing | PGT-A (NGS sequencing) / PGT-M (PCR + linkage analysis) / PGT-SR (SNP array) | 2–4 weeks | Test reports need interpretation by a genetic analyst and should be provided in Chinese or English. |
| Frozen Embryo Transfer | Endometrial preparation (artificial or natural cycle), thaw normal embryos, transfer | 2–4 weeks | Luteal phase support after transfer continues until 10–12 weeks of gestation. |
| Prenatal Diagnosis | Amniocentesis at 16–20 weeks of gestation for fetal karyotype analysis | Second trimester | Prenatal diagnosis is mandatory for all PGT pregnancies and cannot be omitted. |
The entire cycle from starting stimulation to completing transfer typically takes 3–5 months. If PGT-M probe design and family verification are involved, the total cycle may extend to 6–8 months.
Clinical Management Strategies for Complex Situations
In practice, the following special situations require individualized approaches:
- Mosaic Embryos: For low-level mosaicism (<20%) with euploid/normal structure, some centers agree to transfer after genetic counseling, but prenatal diagnosis is required. Mosaicism between 20%–50% is highly controversial; multi-center consultation is recommended.
- No Normal Embryos Available for Transfer: If all embryos are abnormal or fail PGT, assess whether to adjust the stimulation protocol, change sperm source, or consider egg donation.
- Test Failure (No Result): Due to DNA amplification failure or inconclusive chromosomes, consider re-biopsy (if the embryo survives) or alternative preimplantation genetic screening (PGS).
- Undetected Pathogenic Gene: In about 3%–5% of families with genetic diseases, the causative gene cannot be found. In such cases, PGT-M is not possible, but PGT-A can be performed to rule out chromosomal number abnormalities.
- Advanced Maternal Age Combined with Genetic Disease: For women over 38 requiring both PGT-A and PGT-M, the number of retrieved oocytes and normal embryos may be low. Thorough ovarian function assessment (AMH, inhibin B, antral follicle count) is recommended before the cycle.
High-Frequency Clinical Consultation Questions and Evidence-Based Answers
Risk Reminder
Although PGT technology can significantly reduce the risk of specific genetic diseases and chromosomal abnormalities, it is not 100% accurate. Misdiagnosis, missed diagnosis, and missed detection of mosaicism do occur clinically. All PGT pregnancies must undergo prenatal diagnosis (amniocentesis or chorionic villus sampling) and cannot be omitted simply because PGT was performed. Additionally, the potential impact of embryo biopsy on developmental potential, the possibility of test failure, and the risk of having no normal embryos for transfer must be fully understood before treatment. It is recommended to rationally assess the benefits and risks of PGT under the guidance of a genetic counselor at a正规 reproductive center, avoiding irrational decisions due to information asymmetry.
PGT-A PGT-M PGT-SR Chromosomal Aneuploidy Monogenic Disease Thalassemia Balanced Translocation Mosaicism AMH FSH Antral Follicle Count Semen Analysis Genetic Counseling Uterine Cavity Examination Medical Visa Frozen Embryo Transfer Luteal Phase Support Prenatal Diagnosis
When to do overseas IVF tests How far in advance to prepare for overseas IVF Passport validity requirements for overseas IVF What documents are needed for overseas IVF file creation Male partner test items for overseas IVF Female partner test items for overseas IVF Can I do overseas IVF with low AMH What to prepare for advanced maternal age overseas IVF Do I need to prepare my body before overseas IVF
